
  
    
      
        Background_NNP
        Diabetes_NNP mellitus_JJ is_VBZ a_DT chronic_JJ disorder_NN that_WDT has_VBZ been_VBN
        recognized_VBN by_IN the_DT Canadian_JJ government_NN as_IN a_DT major_JJ public_JJ
        health_NN problem_NN with_IN far_RB reaching_VBG consequences_NNS not_RB just_RB for_IN
        its_PRP$ adverse_JJ impact_NN on_IN the_DT health_NN of_IN Canadians_NNPS ,_, but_CC also_RB for_IN
        the_DT economic_JJ burden_NN it_PRP places_VBZ on_IN the_DT health_NN care_NN system_NN ._. In_IN
        recognition_NN of_IN the_DT seriousness_NN of_IN the_DT problem_NN ,_, over_IN 100_CD
        million_CD dollars_NNS has_VBZ been_VBN set_VBN aside_RB to_TO fund_VB the_DT Canadian_NNP
        Diabetes_NNP Strategy_NNP -_: a_DT comprehensive_JJ national_JJ plan_NN focusing_VBG
        on_IN the_DT prevention_NN of_IN diabetes_NN through_IN health_NN promotion_NN and_CC
        education_NN [_NN 1_CD ]_NN ._. Targeting_NNP diabetes_NN in_IN this_DT way_NN is_VBZ not_RB
        surprising_JJ as_IN it_PRP has_VBZ been_VBN estimated_VBN that_IN over_IN 1_CD million_CD
        Canadians_NNPS are_VBP known_VBN to_TO be_VB afflicted_VBN with_IN this_DT condition_NN ,_,
        with_IN 90_CD %_NN having_VBG type_NN 2_CD diabetes_NN [_NN 2_CD ]_NN ._. Furthermore_RB ,_, it_PRP is_VBZ
        acknowledged_VBN that_IN this_DT is_VBZ likely_JJ an_DT underestimation_NN of_IN the_DT
        scope_NN of_IN the_DT disease_NN as_RB up_IN to_TO 1_CD in_IN 2_CD persons_NNS with_IN diabetes_NN
        do_VBP not_RB know_VB they_PRP have_VBP it_PRP [_NN 3_CD ]_NN ._.
        The_DT clinical_JJ consequences_NNS of_IN diabetes_NN can_MD be_VB life_NN
        threatening_VBG and_CC disabling_VBG ._. Diabetes_NNP is_VBZ ranked_VBN as_IN the_DT
        seventh_JJ leading_VBG cause_NN of_IN death_NN in_IN Canada_NNP with_IN at_IN least_JJS
        5_CD ,_, 500_CD deaths_NNS per_IN year_NN attributed_VBD directly_RB to_TO the_DT condition_NN
        itself_PRP ;_: however_RB ,_, this_DT number_NN rises_VBZ dramatically_RB to_TO
        approximately_RB 25_CD ,_, 000_CD when_WRB deaths_NNS from_IN diabetic_JJ
        complications_NNS are_VBP included_VBN [_NN 1_CD ]_NN ._. Coronary_NNP heart_NN disease_NN
        is_VBZ the_DT leading_VBG cause_NN of_IN death_NN in_IN patients_NNS with_IN diabetes_NN [_NN 3_CD
        ]_NN ._.
        There_EX is_VBZ an_DT established_VBN connection_NN between_IN diabetes_NN and_CC
        both_DT macrovascular_NN and_CC microvascular_NN complications_NNS [_NN 4_CD 5_CD 6_CD
        ]_NN ._. It_PRP has_VBZ been_VBN reported_VBN that_IN in_IN Canada_NNP 21_CD %_NN of_IN patients_NNS
        with_IN diabetes_NN have_VBP heart_NN disease_NN [_NN 7_CD ]_NN and_CC that_IN 25_CD %_NN of_IN all_DT
        cardiac_JJ surgery_NN can_MD be_VB attributed_VBN to_TO diabetes_NN ._. It_PRP is_VBZ also_RB
        the_DT leading_VBG cause_NN of_IN both_DT end-stage_JJ renal_JJ disease_NN (_( ESRD_NNP )_)
        and_CC non-traumatic_JJ lower_JJR extremity_NN amputations_NNS (_( LEAs_NNP )_) in_IN
        Canada_NNP ,_, accounting_NN for_IN 32_CD %_NN and_CC 50_CD %_NN of_IN new_JJ cases_NNS ,_,
        respectively_RB [_NN 8_CD 9_CD ]_NN ._. Four_CD hundred_CD new_JJ cases_NNS of_IN blindness_NN
        can_MD be_VB attributed_VBN to_TO diabetes_NN each_DT year_NN ,_, making_VBG diabetes_NN
        the_DT leading_VBG cause_NN of_IN new_JJ blindness_NN in_IN Canadian_JJ adults_NNS [_NN 10_CD
        ]_NN ._. Many_JJ of_IN the_DT complications_NNS of_IN diabetes_NN are_VBP particularly_RB
        debilitating_JJ to_TO the_DT patient_NN ,_, accompanied_VBD not_RB only_RB by_IN a_DT
        personal_JJ physical_JJ and_CC emotional_JJ burden_NN ,_, but_CC a_DT significant_JJ
        economic_JJ one_CD for_IN the_DT patient_NN ,_, family_NN members_NNS ,_, the_DT nation_NN as_IN
        a_DT whole_JJ and_CC the_DT health_NN care_NN system_NN in_IN particular_NN ._. Health_NNP
        Canada_NNP has_VBZ reported_VBN that_IN twice_RB as_IN many_JJ patients_NNS with_IN
        diabetes_NN of_IN working_VBG age_NN reported_VBD disability_NN days_NNS in_IN a_DT set_VBN
        period_NN than_IN their_PRP$ non-diabetic_JJ contemporaries_NNS [_NN 7_CD ]_NN ._.
        In_IN 1993_CD ,_, the_DT economic_JJ burden_NN of_IN diabetes_NN to_TO Canada_NNP was_VBD
        estimated_VBN at_IN $_$ 1_CD ._. 1_LS billion_CD annually_RB [_NN 11_CD ]_NN ._. It_PRP has_VBZ been_VBN
        acknowledged_VBN that_IN this_DT is_VBZ a_DT gross_JJ underestimation_NN as_IN costs_NNS
        related_VBN to_TO the_DT complications_NNS of_IN diabetes_NN were_VBD not_RB included_VBN
        [_NN 7_CD ]_NN ._. A_DT later_JJ projection_NN of_IN $_$ 9_CD billion_CD (_( US_NNP $_$ )_) annually_RB ,_,
        which_WDT included_VBD both_DT direct_JJ and_CC indirect_JJ costs_NNS was_VBD
        established_VBN [_NN 6_CD ]_NN ._. This_DT estimate_NN was_VBD derived_VBN ,_, however_RB ,_,
        based_VBN on_IN published_VBN studies_NNS from_IN the_DT United_NNP States_NNPS (_( US_NNP )_) and_CC
        by_IN making_VBG adjustments_NNS for_IN differences_NNS in_IN population_NN sizes_NNS
        between_IN the_DT two_CD countries_NNS ._. Given_VBN the_DT sources_NNS for_IN this_DT
        estimate_NN ,_, it_PRP could_MD be_VB argued_VBN that_IN it_PRP does_VBZ not_RB accurately_RB
        reflect_VB the_DT cost_NN of_IN diabetes_NN for_IN Canada_NNP ._. Yet_RB ,_, it_PRP is_VBZ not_RB
        uncommon_JJ to_TO see_VB US-based_NNP proxy_NN costs_NNS in_IN Canadian_JJ reports_NNS ,_,
        as_IN there_EX is_VBZ a_DT marked_VBN lack_NN of_IN Canadian-specific_NNP cost_NN
        information_NN relating_VBG to_TO diabetes_NN and_CC its_PRP$ complications_NNS in_IN
        the_DT literature_NN ._.
        Given_VBN the_DT recent_JJ initiatives_NNS of_IN the_DT Canadian_JJ government_NN
        to_TO target_VB diabetes_NN at_IN a_DT national_JJ level_NN ,_, diabetes_NN and_CC its_PRP$
        complications_NNS are_VBP clearly_RB an_DT ongoing_JJ concern_NN for_IN health_NN
        care_NN decision_NN makers_NNS ._. To_TO make_VB informed_VBN decisions_NNS about_IN
        diabetes-related_JJ care_NN and_CC new_JJ therapeutic_JJ interventions_NNS ,_,
        such_JJ as_IN emerging_VBG oral_JJ hypoglycemics_NNS ,_, these_DT decision_NN makers_NNS
        need_VBP to_TO have_VB Canadian-specific_NNP cost_NN information_NN ._. Moreover_RB ,_,
        to_TO ensure_VB an_DT accurate_JJ picture_NN of_IN the_DT cost_NN of_IN managing_VBG
        diabetes_NN the_DT typical_JJ broad_JJ cost_NN estimates_NNS are_VBP not_RB useful_JJ
        because_IN they_PRP do_VBP not_RB distinguish_VB among_IN determinants_NNS of_IN
        resource_NN use_NN and_CC their_PRP$ time_NN course_NN and_CC thus_RB cannot_NN help_NN
        sort_VB out_RP the_DT implications_NNS of_IN changes_NNS in_IN policy_NN ._. For_IN
        example_NN ,_, if_IN a_DT new_JJ drug_NN is_VBZ more_RBR expensive_JJ but_CC reduces_VBZ the_DT
        frequency_NN of_IN hyperglycemia_NN then_RB its_PRP$ economic_JJ assessment_NN
        must_MD address_VB costs_NNS at_IN a_DT more_RBR detailed_JJ level_NN ._. Building_NNP on_IN
        our_PRP$ previously_RB published_VBN work_NN on_IN the_DT Canadian_JJ costs_NNS of_IN
        major_JJ macrovascular_NN complications_NNS of_IN diabetes_NN [_NN 12_CD ]_NN ,_, the_DT
        aim_NN of_IN this_DT paper_NN is_VBZ to_TO provide_VB key_JJ pieces_NNS of_IN that_DT complex_JJ
        economic_JJ puzzle_NN ._. This_DT paper_NN presents_VBZ updated_VBN
        Canadian-specific_NNP cost_NN information_NN for_IN macrovascular_NN
        complications_NNS and_CC new_JJ information_NN on_IN microvascular_NN
        complications_NNS ._. The_DT complications_NNS included_VBN in_IN the_DT analysis_NN
        were_VBD chosen_VBN based_VBN on_IN those_DT considered_VBN in_IN published_VBN
        epidemiological_JJ and_CC economic_JJ models_NNS of_IN diabetes_NN [_NN 13_CD 14_CD 15_CD
        ]_NN ._. Data_NNP are_VBP presented_VBN in_IN a_DT comprehensive_JJ manner_NN so_IN that_IN
        researchers_NNS can_MD examine_VB the_DT cost_NN per_IN patient_NN for_IN each_DT
        complication_NN ._.
      
      
        Methods_NNP
        
          Cost_NN Sources_NNS
          As_IN no_DT one_CD data_NN source_NN was_VBD available_JJ from_IN which_WDT to_TO
          abstract_JJ resource_NN use_NN and_CC cost-relevant_JJ data_NNS for_IN this_DT
          analysis_NN ,_, it_PRP was_VBD necessary_JJ to_TO gather_VB information_NN from_IN a_DT
          variety_NN of_IN pertinent_JJ sources_NNS ._. Acute_NNP inpatient_NN resource_NN
          use_NN and_CC costs_NNS were_VBD derived_VBN primarily_RB from_IN the_DT 1994_CD -_: 95_CD and_CC
          1995_CD -_: 96_CD Ontario_NNP Case_NNP Cost_NN Project_NNP (_( OCCP_NNP )_) databases_NNS [_NN 17_CD
          18_CD ]_NN ._. OCCP_NNP is_VBZ a_DT joint_JJ program_NN of_IN the_DT Ontario_NNP Ministry_NNP of_IN
          Health_NNP and_CC the_DT Ontario_NNP Hospital_NNP Association_NNP ._. It_PRP was_VBD
          initiated_VBN for_IN the_DT purpose_NN of_IN developing_VBG information_NN based_VBN
          on_IN case_NN cost_NN data_NNS for_IN funding_NN and_CC hospital_NN management_NN
          purposes_NNS ._. Patients_NNS with_IN the_DT analysis-relevant_JJ
          complications_NNS were_VBD identified_VBN by_IN a_DT principal_JJ diagnosis_NN
          code_NN (_( Table_NNP 1_LS )_) using_VBG International_NNP Classification_NNP of_IN
          Diseases_NNP (_( ICD-_NNP 9_CD )_) codes_NNS [_NN 19_CD ]_NN ._. Where_WRB possible_JJ ,_, only_RB
          patients_NNS with_IN a_DT secondary_JJ diagnosis_NN code_NN of_IN diabetes_NN were_VBD
          included_VBN in_IN the_DT analysis_NN ._. For_IN example_NN ,_, diabetic_JJ patients_NNS
          admitted_VBN primarily_RB for_IN AMI_NNP were_VBD identified_VBN by_IN a_DT principal_JJ
          diagnosis_NN code_NN of_IN AMI_NNP (_( ICD-_NNP 9_CD :_: 410_CD ._. 0_CD -_: 410_CD ._. 9_CD )_) and_CC a_DT
          secondary_JJ diagnosis_NN code_NN documenting_VBG diabetes_NN
          (_( ICD_NNP 9_CD :_: 250_CD ._. 00_CD -_: 250_CD ._. 93_CD )_) ._. When_WRB the_DT number_NN of_IN diabetic_JJ
          patients_NNS with_IN a_DT specific_JJ complication_NN was_VBD insufficient_JJ to_TO
          perform_VB a_DT reliable_JJ analysis_NN ,_, the_DT population_NN was_VBD expanded_VBN
          to_TO include_VB non-diabetic_JJ patients_NNS with_IN that_DT complication_NN ,_,
          as_IN the_DT focus_NN of_IN the_DT analysis_NN was_VBD to_TO develop_VB the_DT cost_NN of_IN
          managing_VBG the_DT complication_NN and_CC not_RB diabetes_NN ._. Additional_JJ
          cost-related_JJ information_NN based_VBN on_IN Case_NNP Mix_NNP Groupings_NNP
          (_( CMGs_NNP )_) for_IN 1996_CD [_NN 20_CD ]_NN was_VBD also_RB reviewed_VBN and_CC used_VBN when_WRB
          necessary_JJ to_TO supplement_VB the_DT ICD_NNP 9_CD -_: based_VBN data_NNS ._. Acute_NNP care_NN
          hospital_NN cost_NN estimates_NNS include_VBP ,_, all_DT accommodation_NN (_( e_SYM ._. g_SYM ._. ,_,
          routine_JJ and_CC special_JJ care_NN units_NNS )_) ,_, ancillary_JJ services_NNS
          (_( e_SYM ._. g_SYM ._. ,_, pharmacy_NN ,_, laboratory_NN )_) ,_, emergency_NN room_NN ,_, operating_VBG
          room_NN ,_, diagnostic_JJ and_CC therapeutic_JJ procedures_NNS ,_, and_CC
          physician_NN costs_NNS ._. As_IN physician_NN costs_NNS are_VBP not_RB included_VBN in_IN
          the_DT OCCP_NNP data_NN nor_CC reported_VBD in_IN the_DT literature_NN in_IN
          sufficient_JJ detail_NN ,_, it_PRP was_VBD necessary_JJ to_TO develop_VB the_DT
          corresponding_JJ resource_NN use_NN profiles_NNS ._. The_DT OCCP_NNP data_NN and_CC
          the_DT medical_JJ literature_NN were_VBD used_VBN to_TO develop_VB these_DT based_VBN
          on_IN length_NN of_IN stay_NN (_( LOS_NNP )_) ,_, physician_NN service_NN data_NNS ,_, and_CC the_DT
          use_NN of_IN resource_NN intensive_JJ services_NNS such_JJ as_IN the_DT emergency_NN
          room_NN ,_, surgical_JJ procedures_NNS such_JJ as_IN LEA_NNP ,_, special_JJ care_NN
          units_NNS ,_, and_CC consultations_NNS ._.
          Recognizing_NNP the_DT need_NN for_IN continuation_NN of_IN health_NN care_NN
          services_NNS upon_IN discharge_NN ,_, post-acute_JJ care_NN resource_NN use_NN
          profiles_NNS were_VBD developed_VBN ._. To_TO develop_VB these_DT profiles_NNS ,_, data_NNS
          from_IN OCCP_NNP on_IN disposition_NN at_IN discharge_NN were_VBD supplemented_JJ
          with_IN information_NN from_IN the_DT Alberta_NNP Ambulatory_NNP Care_NNP Costing_NNP
          project_NN [_NN 21_CD ]_NN ,_, the_DT Canadian_NNP Diabetes_NNP Association_NNP [_NN 6_CD ]_NN
          ,_, the_DT Heart_NNP Disease_NNP and_CC Stroke_NNP Foundation_NNP of_IN Canada_NNP [_NN 22_CD
          23_CD ]_NN ,_, Health_NNP Canada_NNP [_NN 23_CD 24_CD 25_CD ]_NN ,_, Canadian_JJ clinical_JJ
          practice_NN guidelines_NNS [_NN 26_CD 27_CD 28_CD ]_NN ,_, other_JJ government_NN and_CC
          institutional_JJ reports_NNS [_NN 29_CD 30_CD 31_CD 32_CD 33_CD ]_NN ,_, provider_NN
          survey_NN data_NNS on_IN day_NN care_NN and_CC cardiac_JJ rehabilitation_NN ,_, and_CC
          peer-reviewed_JJ literature_NN [_NN 34_CD 35_CD 36_CD 37_CD 38_CD ]_NN ._. In_IN order_NN to_TO
          maintain_VB consistency_NN with_IN the_DT OCCP_NNP data_NN ,_, Ontario_NNP
          provincial_JJ fee_NN schedules_NNS and_CC formulary_JJ [_NN 39_CD 40_CD 41_CD ]_NN were_VBD
          used_VBN as_IN unit_NN cost_NN sources_NNS for_IN physician-related_JJ care_NN ,_,
          laboratory_NN tests_NNS ,_, and_CC medications_NNS ._. Additional_JJ references_NNS
          used_VBN for_IN specific_JJ complications_NNS are_VBP noted_VBN within_IN the_DT
          appropriate_JJ sections_NNS of_IN this_DT paper_NN ._.
          Reimbursement_NN for_IN health_NN care_NN in_IN Canada_NNP is_VBZ largely_RB
          provincial_JJ rather_RB than_IN federal_JJ ;_: therefore_RB in_IN order_NN to_TO
          derive_VB "_'' national_JJ "_'' costs_NNS ,_, it_PRP was_VBD necessary_JJ to_TO adjust_VB
          provincial_JJ data_NNS ._. Published_VBN health_NN and_CC personal_JJ care_NN data_NNS
          from_IN Statistics_NNPS Canada_NNP [_NN 42_CD ]_NN were_VBD used_VBN to_TO derive_VB a_DT ratio_NN
          between_IN provincial_JJ and_CC national_JJ healthcare_NN costs_NNS by_IN cost_NN
          center_NN for_IN each_DT province_NN ._. Provincial_NNP unit_NN costs_NNS were_VBD then_RB
          adjusted_VBN using_VBG these_DT ratios_NNS to_TO derive_VB the_DT national_JJ
          equivalent_NN ._.
          There_EX are_VBP several_JJ modalities_NNS of_IN treatment_NN for_IN ESRD_NNP
          (_( e_SYM ._. g_SYM ._. ,_, hemodialysis_NNS ,_, peritoneal_JJ dialysis_NN ,_, renal_JJ
          transplant_NN )_) ._. Annual_JJ costs_NNS of_IN caring_VBG for_IN patients_NNS on_IN each_DT
          of_IN these_DT were_VBD applied_VBN to_TO the_DT proportion_NN of_IN patients_NNS
          receiving_VBG that_DT type_NN of_IN treatment_NN to_TO give_VB a_DT weighted_JJ
          average_JJ cost_NN ._. While_IN the_DT distribution_NN was_VBD taken_VBN from_IN 1998_CD
          data_NNS ,_, it_PRP was_VBD assumed_VBN that_IN the_DT ESRD_NNP population_NN is_VBZ in_IN a_DT
          steady_JJ state_NN -_: that_DT is_VBZ ,_, the_DT patients_NNS leaving_VBG the_DT ESRD_NNP
          populations_NNS and_CC the_DT patients_NNS entering_VBG the_DT ESRD_NNP population_NN
          during_IN a_DT given_VBN year_NN have_VBP approximately_RB the_DT same_JJ modality_NN
          distribution_NN such_JJ that_IN the_DT overall_JJ distribution_NN does_VBZ not_RB
          vary_VB significantly_RB from_IN year_NN to_TO year_NN ._. The_DT distribution_NN of_IN
          treatment_NN modalities_NNS for_IN the_DT 1998_CD Canadian_NNP ESRD_NNP
          population_NN was_VBD obtained_VBN from_IN the_DT Canadian_NNP Institute_NNP for_IN
          Health_NNP Information_NNP [_NN 43_CD 44_CD 45_CD ]_NN ._. There_EX is_VBZ a_DT definite_JJ and_CC
          discernable_JJ event_NN cost_NN for_IN renal_JJ transplant_NN versus_CC the_DT
          annual_JJ cost_NN of_IN managing_VBG someone_NN who_WP has_VBZ had_VBD a_DT renal_JJ
          transplant_NN ._. Thus_RB ,_, to_TO estimate_VB the_DT steady-state_JJ cost_NN for_IN
          ESRD_NNP ,_, it_PRP was_VBD necessary_JJ to_TO also_RB estimate_VB the_DT costs_NNS of_IN
          renal_JJ transplantation_NN ._. This_DT was_VBD achieved_VBN by_IN applying_VBG the_DT
          event_NN year_NN cost_NN of_IN a_DT transplant_NN to_TO the_DT proportion_NN of_IN
          patients_NNS who_WP had_VBD received_VBN a_DT renal_JJ transplant_NN during_IN 1998_CD
          (_( transplant_NN year_NN )_) and_CC combining_VBG that_IN with_IN the_DT annual_JJ
          management_NN cost_NN applied_VBN to_TO the_DT proportion_NN receiving_VBG a_DT
          transplant_NN during_IN a_DT previous_JJ year_NN ._. The_DT average_JJ annual_JJ
          costs_NNS of_IN caring_VBG for_IN a_DT patient_NN during_IN the_DT transplant_NN year_NN
          and_CC in_IN a_DT subsequent_JJ year_NN were_VBD obtained_VBN from_IN the_DT
          literature_NN [_NN 46_CD ]_NN ._. The_DT average_JJ annual_JJ cost_NN of_IN treatment_NN
          for_IN hemodialysis_NNS and_CC that_IN for_IN peritoneal_JJ dialysis_NN were_VBD
          taken_VBN from_IN a_DT 1998_CD report_NN published_VBN by_IN the_DT 
          Agence_NNP d_SYM '_POS évaluation_NN des_NNP technologies_NNS et_CC
          des_NNP modes_NNS d_SYM '_POS intervention_NN en_IN santé_NN (_( AÉTMIS_NNP )_) of_IN Québec_NNP
          [_NN 47_CD ]_NN ._. These_DT costs_NNS were_VBD updated_VBN to_TO year_NN 2000_CD and_CC
          "_'' nationalized_VBN "_'' according_VBG to_TO the_DT methodology_NN described_VBD
          above_IN ._.
          The_DT majority_NN of_IN the_DT unit_NN cost_NN and_CC resource_NN use_NN data_NNS
          used_VBN in_IN this_DT analysis_NN were_VBD derived_VBN from_IN Canadian_JJ sources_NNS ._.
          For_IN rare_JJ exceptions_NNS pertaining_VBG to_TO post-acute_JJ care_NN ,_, it_PRP was_VBD
          necessary_JJ to_TO rely_VB on_IN resource_NN use_NN data_NNS from_IN other_JJ
          sources_NNS ._. For_IN example_NN ,_, no_DT Canadian_JJ data_NN were_VBD available_JJ for_IN
          post-acute_JJ care_NN following_VBG discharge_NN from_IN coronary_JJ artery_NN
          bypass_NN graft_NN (_( CABG_NNP )_) or_CC percutaneous_JJ transluminal_NN coronary_JJ
          angioplasty_NN (_( PTCA_NNP )_) readmissions_NNS in_IN diabetic_JJ patients_NNS who_WP
          had_VBD a_DT previous_JJ AMI_NNP ._. Thus_RB ,_, it_PRP was_VBD necessary_JJ to_TO employ_VB
          diagnosis-specific_JJ disposition_NN distributions_NNS for_IN a_DT
          similar_JJ population_NN from_IN five_CD 1996_CD /_NN 97_CD US_NNP all_DT payer_NN state_NN
          databases_NNS to_TO derive_VB initial_JJ post-acute_JJ care_NN patterns_NNS ._. The_DT
          proportions_NNS were_VBD then_RB adjusted_VBN to_TO reflect_VB the_DT difference_NN
          between_IN Canadian_JJ and_CC US_NNP case_NN fatality_NN rates_NNS for_IN diabetic_JJ
          patients_NNS with_IN AMI_NNP ._. Also_RB ,_, although_IN initial_JJ discharge_NN
          disposition_NN data_NNS from_IN Canada_NNP were_VBD used_VBN in_IN the_DT analysis_NN ,_,
          Canadian_JJ data_NNS detailing_VBG transitions_NNS to_TO other_JJ levels_NNS of_IN
          care_NN over_IN time_NN for_IN those_DT with_IN disabling_VBG strokes_NNS were_VBD not_RB
          available_JJ ;_: therefore_RB we_PRP used_VBD our_PRP$ stroke_NN economic_JJ model_NN [_NN
          48_CD ]_NN to_TO derive_VB the_DT state_NN costs_NNS for_IN stroke_NN ._. The_DT long-term_JJ
          transition_NN data_NNS used_VBN in_IN this_DT model_NN come_VB from_IN Sweden_NNP [_NN 49_CD
          ]_NN ._.
          Only_RB direct_JJ medical_JJ costs_NNS ,_, those_DT directly_RB related_VBN to_TO
          delivery_NN of_IN the_DT health_NN care_NN service_NN ,_, are_VBP included_VBN in_IN the_DT
          estimates_NNS reported_VBD here_RB ._. All_DT event_NN and_CC state_NN cost_NN
          estimates_NNS are_VBP reported_VBN in_IN 2000_CD Canadian_JJ dollars_NNS ._. Where_WRB
          2000_CD values_NNS were_VBD not_RB available_JJ ,_, older_JJR estimates_NNS were_VBD
          inflated_VBN using_VBG the_DT Health_NNP Care_NNP Inflation_NN Index_NNP ,_, a_DT
          component_NN of_IN the_DT Consumer_NNP Price_NNP Index_NNP ,_, supplied_VBN by_IN
          Statistics_NNPS Canada_NNP [_NN 42_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Macrovascular_NNP Complications_NNP
          
            AMI_NNP
            It_PRP was_VBD assumed_VBN that_IN all_DT patients_NNS with_IN an_DT AMI_NNP were_VBD
            treated_VBN initially_RB as_IN inpatients_NNS ._. The_DT acute_JJ care_NN portion_NN
            of_IN the_DT event_NN cost_NN is_VBZ comprised_VBN of_IN acute_JJ hospitalization_NN
            (_( $_$ 9_CD ,_, 739_CD )_) ,_, including_VBG physician_NN costs_NNS for_IN the_DT initial_JJ
            event_NN and_CC ambulance_NN costs_NNS (_( $_$ 237_CD )_) for_IN the_DT 52_CD %_NN [_NN 17_CD ]_NN of_IN
            patients_NNS requiring_VBG this_DT type_NN of_IN transport_NN to_TO the_DT
            hospital_NN ._. Subsequent_JJ (_( post-acute_JJ )_) care_NN for_IN AMI_NNP includes_VBZ
            outpatient_NN medical_JJ care_NN ,_, surgical_JJ follow-up_JJ care_NN
            post-_NN CABG_NNP ,_, home_NN health_NN care_NN ,_, cardiac_JJ rehabilitation_NN ,_,
            long_JJ term_NN facility_NN care_NN ,_, and_CC readmissions_NNS within_IN the_DT
            event_NN year_NN for_IN a_DT subsequent_JJ myocardia_NN infarction_NN (_( MI_NNP )_) ,_,
            CABG_NNP ,_, PTCA_NNP or_CC coronary_JJ angiography_NN ._. The_DT subsequent_JJ care_NN
            cost_NN was_VBD developed_VBN by_IN weighting_NN the_DT cost_NN of_IN these_DT
            health_NN care_NN services_NNS by_IN the_DT proportion_NN of_IN patients_NNS
            using_VBG these_DT services_NNS to_TO derive_VB the_DT average_JJ cost_NN per_IN
            person_NN ._. In_IN other_JJ words_NNS ,_, only_RB those_DT who_WP had_VBD a_DT CABG_NNP
            during_IN their_PRP$ stay_NN would_MD have_VB the_DT surgical_JJ follow-up_JJ
            care_NN included_VBN in_IN their_PRP$ cost_NN profile_NN ._. The_DT event_NN year_NN
            cost_NN for_IN AMI_NNP is_VBZ $_$ 18_CD ,_, 635_CD ._.
            State_NN costs_NNS of_IN AMI_NNP were_VBD calculated_VBN to_TO be_VB $_$ 1_CD ,_, 193_CD ,_, per_IN
            patient_NN ,_, per_IN year_NN on_IN average_NN ._. These_DT include_VBP medications_NNS
            (_( i_NNP ._. e_SYM ._. ,_, aspirin_NN ,_, calcium_NN antagonists_NNS ,_, beta_NN blockers_NNS ,_,
            nitrates_NNS ,_, angiotensin_NN converting_VBG inhibitors_NNS ,_, HMG-CoA_NNP
            reductase_NN inhibitors_NNS )_) weighted_VBN by_IN the_DT proportion_NN of_IN
            patients_NNS using_VBG them_PRP ,_, physician_NN visits_NNS ,_, and_CC monitoring_VBG
            cardiology_NN tests_NNS (_( i_NNP ._. e_SYM ._. ,_, electrocardiogram_NN (_( ECG_NNP )_) and_CC
            stress_NN test_NN )_) ._. A_DT small_JJ portion_NN of_IN diabetic_JJ patients_NNS who_WP
            experienced_VBD an_DT AMI_NNP (_( 1_CD ._. 4_LS %_NN )_) required_VBN long-term_JJ care_NN
            facility_NN placement_NN according_VBG to_TO OCCP_NNP data_NNS ._. The_DT cost_NN of_IN
            this_DT care_NN is_VBZ also_RB reflected_VBN in_IN the_DT state_NN cost_NN ._. In_IN
            addition_NN to_TO the_DT sources_NNS listed_VBN previously_RB ,_, several_JJ
            additional_JJ publications_NNS were_VBD used_VBN to_TO obtain_VB information_NN
            for_IN the_DT AMI_NNP resource_NN use_NN profiles_NNS [_NN 50_CD 51_CD 52_CD 53_CD 54_CD 55_CD
            56_CD 57_CD 58_CD 59_CD 60_CD ]_NN ._.
          
          
            Angina_NNP
            On_IN average_NN ,_, the_DT event_NN cost_NN for_IN angina_NN is_VBZ $_$ 3_CD ,_, 183_CD ,_, per_IN
            person_NN ._. This_DT includes_VBZ proportionately_RB weighted_JJ
            estimates_NNS for_IN several_JJ sub-groups_JJ :_: unstable_JJ angina_NN ,_,
            hospitalized_VBN (_( $_$ 9_CD ,_, 661_CD )_) ;_: angina_NN treated_VBN in_IN emergency_NN room_NN
            or_CC on_IN an_DT urgent_JJ basis_NN by_IN a_DT physician_NN as_IN an_DT outpatient_NN
            (_( $_$ 1_CD ,_, 397_CD )_) ;_: and_CC an_DT acute_JJ anginal_NN episode_NN treated_VBN by_IN usual_JJ
            care_NN physician_NN (_( $_$ 1_CD ,_, 230_CD )_) ._. In_IN the_DT absence_NN of_IN
            Canadian-specific_NNP data_NNS ,_, the_DT ratio_NN of_IN 3_CD stable_JJ to_TO 1_CD
            unstable_JJ patient_NN with_IN angina_NN [_NN 61_CD ]_NN ,_, and_CC the_DT 96_CD %_NN
            proportion_NN of_IN unstable_JJ patients_NNS treated_VBN as_IN inpatients_NNS
            were_VBD obtained_VBN from_IN the_DT literature_NN [_NN 62_CD ]_NN ._. OCCP_NNP data_NNS
            revealed_VBD that_IN of_IN those_DT admitted_VBN with_IN angina_NN ,_, 28_CD %_NN were_VBD
            transported_VBN by_IN ambulance_NN ._. Subsequent_JJ first_JJ year_NN costs_NNS
            include_VBP the_DT same_JJ cost_NN centers_NNS as_IN for_IN AMI_NNP except_IN that_IN no_DT
            patients_NNS became_VBD residents_NNS of_IN a_DT nursing_NN home_NN as_IN a_DT
            result_NN ._. The_DT medications_NNS included_VBN in_IN the_DT angina_NN resource_NN
            use_NN profile_NN include_VBP aspirin_NN ,_, calcium_NN antagonists_NNS ,_, beta_NN
            blockers_NNS ,_, nitrates_NNS ,_, angiotensin_NN converting_VBG inhibitors_NNS
            and_CC statins_NNS ._. The_DT costs_NNS for_IN these_DT drugs_NNS were_VBD weighted_JJ
            based_VBN on_IN reported_VBD proportions_NNS of_IN angina_NN patients_NNS using_VBG
            them_PRP [_NN 54_CD 59_CD 63_CD ]_NN ._.
            State_NN costs_NNS of_IN angina_NN were_VBD calculated_VBN to_TO be_VB $_$ 1_CD ,_, 485_CD ,_,
            per_IN patient_NN ,_, per_IN year_NN on_IN average_NN ._. These_DT included_VBD
            medications_NNS ,_, physician_NN visits_NNS ,_, laboratory_NN tests_NNS and_CC
            monitoring_VBG cardiology_NN tests_NNS (_( i_NNP ._. e_SYM ._. ,_, ECG_NNP and_CC stress_NN
            test_NN )_) ._. Additional_JJ resource_NN use_NN information_NN regarding_VBG
            visits_NNS and_CC tests_NNS was_VBD abstracted_JJ from_IN published_VBN sources_NNS
            [_NN 27_CD 64_CD 65_CD ]_NN ._.
          
          
            Ischemic_NNP Stroke_NNP
            The_DT disabling_VBG consequences_NNS of_IN stroke_NN are_VBP reflected_VBN
            in_IN the_DT first_JJ year_NN management_NN costs_NNS ,_, as_IN more_JJR patients_NNS
            require_VBP continuing_VBG care_NN services_NNS after_IN discharge_NN from_IN
            the_DT hospital_NN ._. OCCP_NNP data_NNS and_CC information_NN from_IN published_VBN
            literature_NN [_NN 66_CD 67_CD 68_CD 69_CD 70_CD 71_CD ]_NN were_VBD used_VBN to_TO determine_VB
            post-acute_JJ care_NN placement_NN for_IN rehabilitation_NN ,_,
            readmission_NN for_IN a_DT subsequent_JJ stroke_NN events_NNS and_CC long_JJ
            term_NN care_NN in_IN the_DT first_JJ year_NN ._. Acute_NNP care_NN comprises_VBZ only_RB
            27_CD %_NN (_( $_$ 8_CD ,_, 822_CD )_) of_IN the_DT mean_JJ event_NN cost_NN for_IN ischemic_JJ stroke_NN
            (_( $_$ 33_CD ,_, 256_CD )_) ._. This_DT is_VBZ half_NN of_IN the_DT AMI_NNP proportion_NN (_( 53_CD %_NN )_) ,_,
            highlighting_VBG the_DT effect_NN of_IN increased_VBN need_NN for_IN
            post-acute_JJ care_NN in_IN stroke_NN ._.
            The_DT mean_JJ annual_JJ state_NN cost_NN is_VBZ $_$ 8_CD ,_, 769_CD and_CC reflects_VBZ
            outpatient_NN monitoring_NN ,_, medications_NNS (_( i_NNP ._. e_SYM ._. ,_, aspirin_NN )_) and_CC
            the_DT increased_VBN need_NN for_IN day_NN care_NN ,_, durable_JJ medical_JJ
            equipment_NN and_CC permanent_JJ long-term_JJ care_NN in_IN this_DT patient_NN
            population_NN ._.
          
          
            TIA_NNP
            It_PRP was_VBD assumed_VBN for_IN this_DT analysis_NN that_IN all_DT patients_NNS
            diagnosed_VBN with_IN a_DT TIA_NNP who_WP are_VBP diabetic_JJ would_MD receive_VB
            inpatient_NN care_NN initially_RB ._. It_PRP was_VBD also_RB assumed_VBN that_IN all_DT
            TIAs_NNP are_VBP truly_RB transient_JJ -_: an_DT assumption_NN that_WDT finds_VBZ
            some_DT support_NN in_IN the_DT OCCP_NNP TIA_NNP data_NNS where_WRB the_DT only_RB
            post-acute_JJ discharge_NN dispositions_NNS were_VBD home_NN (_( outpatient_NN
            care_NN )_) ,_, home_NN health_NN care_NN and_CC rehabilitation_NN ._. Thus_RB ,_, no_DT
            health_NN care_NN services_NNS associated_VBN with_IN permanent_JJ residual_JJ
            disability_NN (_( e_SYM ._. g_SYM ._. ,_, long_JJ term_NN care_NN placement_NN )_) were_VBD
            considered_VBN for_IN inclusion_NN in_IN the_DT cost_NN estimate_NN ._.
            Additional_JJ resource_NN use_NN data_NNS were_VBD obtained_VBN from_IN Nova_NNP
            Scotia_NNP [_NN 72_CD ]_NN ._. The_DT mean_JJ event_NN cost_NN for_IN TIA_NNP is_VBZ $_$ 3_CD ,_, 262_CD ._.
            Aspirin_NNP is_VBZ the_DT only_JJ medication_NN included_VBN in_IN the_DT cost_NN
            profiles_NNS for_IN TIA_NNP ._. Thus_RB ,_, the_DT mean_JJ state_NN cost_NN of_IN $_$ 73_CD for_IN
            TIA_NNP is_VBZ based_VBN on_IN monitoring_VBG visits_NNS to_TO a_DT physician_NN and_CC
            daily_JJ aspirin_NN ._.
          
        
        
          Microvascular_NNP Complications_NNP
          
            Nephropathy_NNP
            The_DT costs_NNS for_IN microalbuminuria_NN and_CC gross_JJ proteinuria_NN
            are_VBP based_VBN primarily_RB on_IN recommendations_NNS from_IN Canadian_JJ
            clinical_JJ practice_NN guidelines_NNS and_CC consist_VBP only_RB of_IN
            laboratory_NN tests_NNS on_IN urine_NN and_CC physician_NN visits_NNS ._. The_DT use_NN
            of_IN ACE_NNP Inhibitors_NNP is_VBZ discussed_VBN in_IN the_DT literature_NN with_IN
            regard_NN to_TO the_DT prevention_NN of_IN progression_NN of_IN renal_JJ
            disease_NN ._. The_DT Canadian_JJ clinical_JJ practice_NN recommendations_NNS
            of_IN 1998_CD recognize_VB that_IN some_DT patients_NNS with_IN type_NN 2_CD
            diabetes_NN who_WP have_VBP proteinuria_NN may_MD benefit_VB from_IN this_DT
            type_NN of_IN therapy_NN [_NN 27_CD ]_NN and_CC suggest_VBP that_IN ACE_NNP Inhibitors_NNP
            should_MD be_VB considered_VBN ,_, but_CC do_VBP not_RB recommend_VB them_PRP for_IN all_DT
            patients_NNS ._. As_IN no_DT data_NNS are_VBP available_JJ pertaining_VBG to_TO the_DT
            proportion_NN of_IN patients_NNS on_IN this_DT type_NN of_IN therapy_NN solely_RB
            for_IN the_DT purpose_NN of_IN preventing_VBG further_JJ renal_JJ
            deterioration_NN ,_, the_DT cost_NN is_VBZ not_RB included_VBN in_IN the_DT current_JJ
            estimate_NN ._. The_DT event_NN cost_NN for_IN microalbuminuria_NN is_VBZ $_$ 62_CD ;_:
            $_$ 54_CD for_IN gross_JJ proteinuria_NN ._. The_DT state_NN costs_NNS are_VBP $_$ 10_CD and_CC
            $_$ 18_CD for_IN microalbuminuria_NN and_CC gross_JJ proteinuria_NN ,_,
            respectively_RB ._.
            The_DT annual_JJ cost_NN (_( $_$ 63_CD ,_, 045_CD )_) of_IN caring_VBG for_IN a_DT patient_NN
            with_IN ESRD_NNP represents_VBZ a_DT weighted_JJ average_NN of_IN the_DT annual_JJ
            costs_NNS for_IN hemodialysis_NNS ,_, peritoneal_JJ dialysis_NN ,_, and_CC renal_JJ
            transplant_NN ._.
          
          
            Retinopathy_NNP
            The_DT costs_NNS for_IN macular_NN edema_NN and_CC proliferative_JJ
            retinopathy_NN are_VBP comprised_VBN of_IN physician_NN visits_NNS ,_,
            ophthalmology_NN consults_NNS ,_, and_CC the_DT use_NN of_IN diagnostic_JJ and_CC
            therapeutic_JJ eye_NN procedures_NNS (_( i_NNP ._. e_SYM ._. ,_, color_JJ fundus_JJ
            photography_NN ,_, fluorescein_NN angiography_NN and_CC
            photocoagulation_NN )_) ._. Published_VBN Canadian_JJ clinical_JJ practice_NN
            guidelines_NNS for_IN diabetic_JJ retinopathy_NN were_VBD the_DT source_NN for_IN
            resource_NN use_NN [_NN 27_CD 28_CD ]_NN ._. The_DT mean_JJ event_NN costs_NNS for_IN these_DT
            complications_NNS are_VBP $_$ 423_CD for_IN macular_NN edema_NN and_CC $_$ 379_CD for_IN
            proliferative_JJ retinopathy_NN ,_, respectively_RB when_WRB
            photocoagulation_NN is_VBZ used_VBN ._. If_IN both_DT conditions_NNS are_VBP
            present_JJ in_IN one_CD patient_NN ,_, the_DT event_NN cost_NN rises_VBZ to_TO $_$ 495_CD ._.
            The_DT state_NN cost_NN of_IN $_$ 40_CD ,_, comprised_VBN of_IN additional_JJ
            monitoring_NN by_IN an_DT ophthalmologist_NN ,_, is_VBZ the_DT same_JJ for_IN both_DT
            conditions_NNS ._.
            Blindness_NNP does_VBZ not_RB have_VB an_DT event_NN cost_NN ,_, as_IN there_EX is_VBZ
            no_DT event_NN per_IN se_FW ._. Rather_RB ,_, the_DT decent_JJ into_IN blindness_NN due_JJ
            to_TO diabetes_NN is_VBZ the_DT result_NN of_IN either_DT failure_NN to_TO detect_VB
            or_CC failure_NN to_TO treat_VB retinopathy_NN at_IN an_DT earlier_JJR stage_NN ._.
            Unfortunately_RB ,_, there_EX has_VBZ been_VBN little_JJ information_NN
            developed_VBN on_IN the_DT annual_JJ cost_NN of_IN blindness_NN ,_, let_VB alone_RB
            the_DT annual_JJ direct_JJ medical_JJ cost_NN in_IN any_DT country_NN ._. No_DT
            information_NN could_MD be_VB found_VBN from_IN the_DT literature_NN ,_,
            government_NN agencies_NNS or_CC relevant_JJ private_JJ agencies_NNS that_WDT
            deal_NN with_IN the_DT blind_JJ ._. One_CD of_IN the_DT only_RB available_JJ sources_NNS
            for_IN direct_JJ medical_JJ costs_NNS is_VBZ a_DT published_VBN US-based_NNP cost_NN
            from_IN 1990_CD [_NN 73_CD ]_NN ._. By_IN converting_VBG this_DT figure_NN to_TO
            Canadian_JJ dollars_NNS using_VBG the_DT 1990_CD exchange_NN rate_NN of_IN
            $_$ 0_CD ._. 8572_CD and_CC then_RB inflating_VBG the_DT Canadian_JJ value_NN to_TO a_DT 2000_CD
            Canadian_JJ dollar_NN values_VBZ a_DT state_NN cost_NN of_IN $_$ 2_CD ,_, 111_CD for_IN
            blindness_NN was_VBD estimated_VBN ._.
          
          
            Neuropathy_NNP
            Three_CD levels_NNS of_IN neuropathy_NN were_VBD examined_VBN in_IN this_DT
            analysis_NN :_: symptomatic_JJ neuropathy_NN ,_, and_CC first_JJ and_CC second_JJ
            LEA_NNP ._. The_DT resource_NN use_NN for_IN symptomatic_JJ neuropathy_NN was_VBD
            limited_VBN to_TO diagnosis_NN and_CC monitoring_VBG ,_, as_IN there_EX is_VBZ no_DT
            specific_JJ treatment_NN for_IN this_DT condition_NN ,_, and_CC use_NN of_IN the_DT
            palliative_JJ options_NNS available_JJ is_VBZ not_RB consistent_JJ ._. Thus_RB ,_,
            this_DT is_VBZ likely_JJ an_DT underestimation_NN of_IN the_DT cost_NN for_IN this_DT
            complication_NN ._. Published_VBN clinical_JJ practice_NN guidelines_NNS
            were_VBD used_VBN to_TO establish_VB the_DT event_NN year_NN resource_NN use_NN
            profile_NN [_NN 27_CD 28_CD 74_CD ]_NN ._. The_DT event_NN year_NN cost_NN is_VBZ $_$ 148_CD per_IN
            person_NN ._. There_EX is_VBZ no_DT state_NN cost_NN as_IN beyond_IN the_DT initial_JJ
            diagnostic_JJ tests_NNS ,_, there_EX is_VBZ no_DT further_JJ management_NN
            recommended_VBD ._.
            Neuropathy_NNP and_CC foot_NN ulcers_NNS can_MD lead_VB to_TO amputations_NNS ._.
            These_DT can_MD occur_VB at_IN various_JJ levels_NNS :_: toe_NN ,_, foot_NN ,_, below_IN the_DT
            knee_NN and_CC above_IN the_DT knee_NN ._. Thus_RB ,_, the_DT cost_NN for_IN each_DT type_NN
            of_IN amputation_NN was_VBD calculated_VBN using_VBG OCCP_NNP data_NNS and_CC then_RB
            weighted_VBN by_IN the_DT proportion_NN of_IN diabetic_JJ patients_NNS having_VBG
            that_DT type_NN of_IN surgery_NN to_TO determine_VB the_DT overall_JJ event_NN
            cost_NN for_IN a_DT LEA_NNP ._. Furthermore_RB ,_, it_PRP has_VBZ been_VBN reported_VBN that_IN
            50_CD %_NN of_IN patients_NNS with_IN diabetes_NN who_WP have_VBP a_DT LEA_NNP will_MD go_VB on_IN
            to_TO have_VB a_DT second_JJ LEA_NNP within_IN 5_CD years_NNS [_NN 75_CD ]_NN ;_: therefore_RB ,_,
            event_NN costs_NNS for_IN a_DT first_JJ and_CC second_JJ amputation_NN were_VBD
            calculated_VBN separately_RB ._. As_IN it_PRP is_VBZ not_RB possible_JJ to_TO discern_VB
            first_JJ versus_CC second_JJ LEA_NNP in_IN a_DT claims_NNS database_NN ,_,
            proportions_NNS by_IN type_NN of_IN amputation_NN were_VBD used_VBN to_TO
            differentiate_VB between_IN first_JJ and_CC second_JJ amputation_NN
            inpatient_NN costs_NNS ._. No_DT Canadian_JJ data_NN were_VBD available_JJ to_TO
            make_VB this_DT differentiation_NN possible_JJ at_IN all_DT of_IN the_DT
            necessary_JJ levels_NNS required_VBN for_IN this_DT analysis_NN ;_: therefore_RB ,_,
            a_DT US_NNP based_VBD study_NN from_IN Rochester_NNP ,_, MN_NNP was_VBD used_VBN to_TO provide_VB
            proportions_NNS of_IN amputation_NN type_NN for_IN first_JJ and_CC second_JJ LEA_NNP
            [_NN 76_CD ]_NN ._. The_DT cost_NN of_IN an_DT above_IN the_DT knee_NN amputation_NN (_( AKA_NNP )_)
            is_VBZ considerably_RB more_JJR than_IN that_DT of_IN a_DT toe_NN amputation_NN ,_, not_RB
            just_RB in_IN the_DT hospital_NN (_( $_$ 19_CD ,_, 760_CD versus_CC $_$ 6_CD ,_, 460_CD )_) but_CC also_RB
            beyond_IN due_JJ to_TO the_DT significantly_RB higher_JJR level_NN of_IN
            disability_NN resulting_VBG from_IN an_DT AKA_NNP ._. Information_NNP regarding_VBG
            post-acute_JJ care_NN dispositions_NNS ,_, rehabilitation_NN ,_,
            readmissions_NNS for_IN debridement_NN and_CC major_JJ stump_NN revisions_NNS ,_,
            and_CC use_NN of_IN prosthetic_JJ devises_VBZ and_CC durable_JJ medical_JJ
            equipment_NN were_VBD obtained_VBN from_IN the_DT OCCP_NNP database_NN ,_,
            provider_NN surveys_NNS and_CC publications_NNS [_NN 77_CD 78_CD 79_CD ]_NN ._. The_DT
            increase_NN in_IN event_NN cost_NN from_IN first_JJ (_( $_$ 24_CD ,_, 583_CD )_) to_TO second_JJ
            (_( $_$ 26_CD ,_, 077_CD )_) represents_VBZ a_DT shift_NN to_TO a_DT higher_JJR anatomical_JJ ,_,
            and_CC thus_RB ,_, more_RBR costly_JJ level_NN of_IN amputation_NN for_IN the_DT
            second_JJ amputation_NN as_IN noted_VBN in_IN the_DT Rochester_NNP study_NN [_NN 76_CD
            ]_NN ._.
            LEA_NNP can_MD be_VB a_DT very_RB disabling_VBG event_NN for_IN a_DT patient_NN and_CC
            has_VBZ consequences_NNS beyond_IN the_DT event_NN year_NN ._. No_DT published_VBN
            information_NN was_VBD identified_VBN that_WDT could_MD isolate_VB ongoing_JJ
            annual_JJ direct_JJ management_NN costs_NNS related_VBN to_TO LEA_NNP versus_CC
            usual_JJ management_NN of_IN a_DT patient_NN with_IN diabetes_NN ,_, thus_RB ,_, only_RB
            costs_VBZ directly_RB related_VBN to_TO the_DT LEA_NNP (_( i_NNP ._. e_SYM ._. ,_, long-term_JJ
            facility_NN residential_JJ care_NN and_CC the_DT management_NN ,_, refitting_VBG
            of_IN the_DT prosthetic_JJ device_NN )_) are_VBP included_VBN in_IN the_DT state_NN
            cost_NN for_IN LEA_NNP ._. The_DT state_NN cost_NN for_IN LEA_NNP 1_CD is_VBZ $_$ 1_CD ,_, 020_CD ._. To_TO
            avoid_VB double-counting_JJ ,_, given_VBN the_DT cost_NN components_NNS of_IN the_DT
            LEA_NNP state_NN profile_NN ,_, the_DT state_NN cost_NN of_IN the_DT second_JJ LEA_NNP is_VBZ
            conservatively_RB assumed_VBN to_TO be_VB zero_CD as_IN it_PRP was_VBD not_RB
            possible_JJ to_TO discern_VB which_WDT prosthesis_NNS related_VBD costs_NNS
            would_MD be_VB specific_JJ to_TO the_DT second_JJ prosthesis_NNS versus_CC costs_NNS
            already_RB included_VBN in_IN the_DT state_NN cost_NN for_IN LEA_NNP 1_CD [_NN 77_CD 80_CD 81_CD
            82_CD ]_NN ._.
          
          
            Diabetic_NNP Foot_NNP Ulcer_NNP
            For_IN the_DT purpose_NN of_IN this_DT analysis_NN ,_, foot_NN ulcers_NNS are_VBP
            defined_VBN as_IN those_DT that_WDT heal_VB without_IN amputation_NN or_CC
            vascular_NN surgery_NN ._. Since_IN not_RB all_DT diabetic_JJ foot_NN ulcers_NNS
            are_VBP treated_VBN in_IN an_DT inpatient_NN setting_VBG ,_, the_DT event_NN cost_NN is_VBZ
            a_DT weighted_JJ average_NN of_IN inpatient_NN (_( $_$ 7_CD ,_, 802_CD )_) and_CC outpatient_NN
            care_NN costs_NNS (_( $_$ 1_CD ,_, 042_CD )_) ._. OCCP_NNP data_NNS and_CC information_NN from_IN the_DT
            literature_NN were_VBD used_VBN to_TO determine_VB proportions_NNS and_CC
            resource_NN use_NN [_NN 21_CD 83_CD 84_CD 85_CD ]_NN ._. The_DT event_NN cost_NN for_IN
            diabetic_JJ foot_NN ulcer_NN is_VBZ $_$ 2_CD ,_, 183_CD per_IN person_NN ,_, on_IN average_NN ._.
            There_EX is_VBZ no_DT state_NN cost_NN calculated_VBN for_IN this_DT complication_NN
            as_IN it_PRP is_VBZ considered_VBN to_TO be_VB episodic_JJ ._.
          
          
            Hypoglycemia_NNP
            For_IN the_DT purpose_NN of_IN this_DT analysis_NN ,_, only_RB hypoglycemic_JJ
            events_NNS that_WDT generate_VBP the_DT use_NN of_IN medication_NN or_CC formal_JJ
            health_NN care_NN services_NNS (_( formal_JJ care_NN )_) were_VBD included_VBN ._. Three_CD
            levels_NNS of_IN resource_NN use_NN were_VBD considered_VBN for_IN this_DT
            condition_NN :_: the_DT lowest_JJS level_NN of_IN formal_JJ care_NN is_VBZ
            self-treatment_JJ with_IN a_DT glucagon_NN injection_NN and_CC no_DT
            intervention_NN from_IN medical_JJ personnel_NNS (_( $_$ 24_CD )_) ;_: the_DT middle_JJ
            level_NN is_VBZ an_DT ambulatory_JJ care_NN or_CC emergency_NN room_NN
            consultation_NN (_( $_$ 194_CD )_) ;_: the_DT highest_JJS level_NN is_VBZ
            hospitalization_NN with_IN a_DT follow-up_JJ physician_NN visit_NN
            (_( $_$ 4_CD ,_, 184_CD )_) ._. A_DT cost_NN was_VBD developed_VBN for_IN each_DT level_NN ._. An_DT
            overall_JJ hypoglycemic_JJ event_NN cost_NN was_VBD derived_VBN by_IN applying_VBG
            the_DT appropriate_JJ weights_NNS ,_, taken_VBN from_IN US_NNP studies_NNS ,_, as_IN no_DT
            Canadian_JJ data_NN were_VBD available_JJ [_NN 86_CD 87_CD ]_NN ._. Only_RB 1_CD %_NN of_IN
            those_DT experiencing_VBG a_DT hypoglycemic_JJ event_NN are_VBP assigned_VBN
            inpatient_NN costs_NNS ._. The_DT event_NN cost_NN for_IN this_DT episodic_JJ
            complication_NN is_VBZ $_$ 111_CD ._.
          
        
      
      
        Discussion_NNP
        Diabetes_NNP and_CC its_PRP$ complications_NNS are_VBP major_JJ health_NN care_NN
        problems_NNS for_IN Canada_NNP ._. Nearly_RB 6_CD %_NN of_IN the_DT Canadian_JJ population_NN
        is_VBZ affected_VBN and_CC First_CD Nations_NNPS have_VBP one_CD of_IN the_DT highest_JJS
        reported_VBN prevalences_NNS (_( 26_CD %_NN )_) in_IN an_DT indigenous_JJ population_NN [_NN 88_CD
        ]_NN ._. It_PRP has_VBZ been_VBN recognized_VBN that_DT health_NN care_NN expenditures_NNS
        related_VBN to_TO the_DT complications_NNS of_IN diabetes_NN account_NN for_IN a_DT
        substantial_JJ proportion_NN of_IN the_DT public_JJ health_NN care_NN budget_NN [_NN
        89_CD ]_NN and_CC that_WDT related_VBD costs_NNS are_VBP likely_JJ to_TO escalate_VB as_IN the_DT
        population_NN ages_NNS ._. Yet_RB ,_, given_VBN the_DT size_NN of_IN the_DT problem_NN ,_, the_DT
        acknowledged_VBN concern_NN and_CC initiatives_NNS undertaken_VBN to_TO address_VB
        diabetes_NN on_IN a_DT national_JJ level_NN and_CC for_IN the_DT native_JJ Canadian_JJ
        population_NN in_IN particular_JJ ,_, it_PRP is_VBZ surprising_JJ that_IN there_EX is_VBZ so_RB
        little_RB available_JJ Canadian_JJ information_NN about_IN the_DT cost_NN of_IN the_DT
        complications_NNS of_IN diabetes_NN ,_, particularly_RB at_IN a_DT level_NN detailed_JJ
        enough_RB to_TO be_VB meaningful_JJ to_TO decision_NN makers_NNS or_CC those_DT doing_VBG
        economic_JJ analyses_NNS ._. The_DT purpose_NN of_IN this_DT paper_NN is_VBZ to_TO provide_VB
        comprehensive_JJ cost_NN estimates_NNS for_IN several_JJ common_JJ
        complications_NNS of_IN diabetes_NN in_IN a_DT manner_NN that_WDT can_MD be_VB useful_JJ to_TO
        interested_JJ parties_NNS ._.
        A_DT main_JJ goal_NN of_IN this_DT analysis_NN was_VBD to_TO develop_VB
        Canadian-specific_NNP cost_NN estimates_NNS using_VBG Canadian_JJ unit_NN cost_NN
        and_CC resource_NN use_NN information_NN wherever_WRB possible_JJ ._. This_DT point_NN
        is_VBZ stressed_VBN as_IN the_DT importance_NN of_IN using_VBG country-specific_JJ
        data_NNS in_IN an_DT economic_JJ analysis_NN cannot_NN be_VB ignored_VBN ._. As_IN noted_VBD
        earlier_RBR ,_, it_PRP is_VBZ not_RB uncommon_JJ to_TO find_VB US_NNP or_CC European_JJ costs_NNS
        for_IN diabetes_NN used_VBN as_IN a_DT proxy_NN for_IN Canadian_JJ costs_NNS ,_, even_RB in_IN
        official_JJ reports_NNS [_NN 6_CD ]_NN ;_: however_RB ,_, the_DT true_JJ relevance_NN of_IN
        these_DT costs_NNS to_TO a_DT Canadian_JJ population_NN can_MD only_RB be_VB assumed_VBN ._.
        In_IN previously_RB published_VBN work_NN [_NN 12_CD ]_NN ,_, we_PRP have_VBP shown_VBN that_IN
        the_DT use_NN of_IN US_NNP data_NNS ,_, even_RB when_WRB Canadian_JJ unit_NN costs_NNS are_VBP used_VBN
        can_MD lead_VB to_TO inaccurate_JJ ,_, albeit_IN well-intentioned_JJ estimates_NNS ._.
        In_IN that_DT example_NN ,_, a_DT difference_NN of_IN approximately_RB $_$ 1_CD ,_, 400_CD
        dollars_NNS in_IN the_DT state_NN cost_NN for_IN stroke_NN was_VBD noted_VBN when_WRB US_NNP
        resource_NN use_NN data_NNS were_VBD replaced_VBN with_IN Canadian_JJ data_NNS ._. As_IN the_DT
        state_NN cost_NN is_VBZ applied_VBN to_TO every_DT year_NN the_DT patient_NN is_VBZ in_IN that_DT
        health_NN state_NN ,_, a_DT substantial_JJ miscalculation_NN of_IN the_DT lifetime_NN
        cost_NN attributed_VBD to_TO stroke_NN would_MD have_VB been_VBN produced_VBN ,_, even_RB
        though_IN it_PRP would_MD have_VB been_VBN based_VBN on_IN the_DT best_JJS available_JJ data_NNS
        and_CC accepted_VBD as_IN a_DT reasonable_JJ proxy_NN in_IN the_DT absence_NN of_IN
        Canadian_JJ data_NNS ._.
        Although_IN there_EX may_MD be_VB clinical_JJ consensus_NN on_IN the_DT
        management_NN of_IN a_DT condition_NN ,_, type_NN and_CC availability_NN of_IN health_NN
        care_NN services_NNS ,_, medical_JJ practice_NN patterns_NNS ,_, and_CC access_NN to_TO
        care_VB will_MD affect_VB the_DT type_NN and_CC level_NN of_IN care_NN actually_RB
        delivered_VBD ._. Thus_RB ,_, differences_NNS beyond_IN those_DT relating_VBG to_TO just_RB
        monetary_JJ conditions_NNS must_MD be_VB acknowledged_VBN when_WRB using_VBG proxy_NN
        data_NNS ,_, as_RB sometimes_RB their_PRP$ use_NN is_VBZ unavoidable_JJ ._. While_IN every_DT
        effort_NN was_VBD made_VBN to_TO use_VB only_RB Canadian-based_NNP data_NNS in_IN this_DT
        analysis_NN ,_, it_PRP was_VBD not_RB possible_JJ in_IN some_DT cases_NNS (_( e_SYM ._. g_SYM ._. ,_, aspects_NNS
        of_IN LEA_NNP and_CC of_IN AMI_NNP )_) ._. Does_VBZ that_WDT mean_VBP that_IN those_DT estimates_NNS
        relying_VBG on_IN some_DT data_NNS from_IN elsewhere_RB should_MD be_VB ignored_VBN ?_. We_PRP
        would_MD argue_VB "_'' no_DT "_'' even_RB in_IN the_DT face_NN of_IN the_DT cautionary_JJ words_NNS
        provided_VBN above_IN ._. All_DT unit_NN costs_NNS used_VBN in_IN this_DT analysis_NN are_VBP
        from_IN Canadian_JJ sources_NNS and_CC the_DT vast_JJ majority_NN of_IN resource_NN use_NN
        data_NNS are_VBP also_RB Canadian_JJ ._. The_DT estimates_NNS provided_VBN here_RB are_VBP the_DT
        closest_JJS reflection_NN possible_JJ of_IN the_DT costs_NNS for_IN these_DT
        complications_NNS in_IN Canada_NNP given_VBN the_DT data_NNS available_JJ at_IN the_DT
        time_NN of_IN the_DT analysis_NN ._. They_PRP can_MD and_CC should_MD be_VB used_VBN ,_, but_CC with_IN
        an_DT understanding_NN that_IN for_IN the_DT few_JJ estimates_NNS where_WRB proxy_NN
        data_NNS have_VBP been_VBN employed_VBN ,_, the_DT cost_NN may_MD not_RB be_VB a_DT precise_JJ
        estimate_NN for_IN Canada_NNP ._.
        Apart_RB from_IN the_DT use_NN of_IN proxy_NN data_NNS ,_, some_DT of_IN the_DT
        complication_NN costs_NNS may_MD be_VB overestimated_JJ or_CC underestimated_VBN
        due_JJ to_TO the_DT content_NN of_IN the_DT resource_NN use_NN profile_NN ._. For_IN
        example_NN ,_, the_DT TIA_NNP estimate_NN may_MD be_VB an_DT overestimation_NN of_IN the_DT
        event_NN cost_NN if_IN a_DT substantial_JJ number_NN of_IN such_JJ patients_NNS are_VBP not_RB
        treated_VBN in_IN the_DT hospital_NN initially_RB in_IN Canada_NNP ._. If_IN the_DT TIA_NNP
        profile_NN were_VBD to_TO include_VB a_DT large_JJ proportion_NN of_IN patients_NNS
        treated_VBN initially_RB as_IN outpatients_NNS ,_, the_DT event_NN cost_NN for_IN TIA_NNP
        could_MD be_VB decreased_VBN by_IN as_RB much_JJ as_IN 45_CD %_NN [_NN 16_CD 90_CD ]_NN ._. It_PRP is_VBZ
        likely_JJ that_IN the_DT foot_NN ulcer_NN ,_, LEA_NNP and_CC symptomatic_JJ neuropathy_NN
        estimates_NNS are_VBP underestimated_VBN as_IN data_NNS for_IN some_DT potentially_RB
        relevant_JJ cost_NN components_NNS were_VBD not_RB available_JJ ._. The_DT degree_NN of_IN
        uncertainty_NN in_IN these_DT estimates_NNS cannot_NN be_VB quantified_VBN because_IN
        in_IN most_JJS cases_VBZ the_DT source_NN data_NN do_VBP not_RB provide_VB it_PRP and_CC there_EX
        are_VBP reasons_NNS other_JJ than_IN statistical_JJ imprecision_NN that_WDT may_MD
        also_RB contribute_VB ._.
        The_DT use_NN of_IN administrative_JJ databases_NNS ,_, as_IN in_IN this_DT
        analysis_NN ,_, brings_VBZ with_IN it_PRP concern_NN regarding_VBG the_DT accuracy_NN of_IN
        ICD-_NNP 9_CD coding_VBG ._. Published_VBN coding_VBG error_NN rates_NNS relating_VBG to_TO
        diabetes_NN in_IN Canada_NNP could_MD not_RB be_VB identified_VBN ._. While_IN a_DT study_NN
        from_IN the_DT U_NNP ._. K_NNP ._. in_IN the_DT early_JJ 1990_CD s_VBZ showed_VBN that_IN there_EX was_VBD
        under-coding_JJ of_IN diabetes_NN in_IN hospital_NN records_NNS [_NN 91_CD ]_NN ,_, later_RB
        studies_VBZ from_IN the_DT US_NNP have_VBP reported_VBN a_DT greater_JJR than_IN 90_CD %_NN
        accuracy_NN rate_NN in_IN coding_VBG of_IN major_JJ macrovascular_NN
        complications_NNS in_IN diabetic_JJ patients_NNS [_NN 92_CD ]_NN ._. The_DT coding_VBG
        error_NN rate_NN in_IN the_DT OCCP_NNP data_NN is_VBZ unknown_JJ ,_, but_CC for_IN the_DT purpose_NN
        of_IN this_DT analysis_NN ,_, it_PRP is_VBZ only_RB of_IN concern_NN if_IN there_EX is_VBZ a_DT
        cost-relevant_JJ bias_NN in_IN the_DT cases_NNS included_VBD ._. It_PRP is_VBZ unclear_JJ
        whether_IN such_JJ a_DT bias_NN exists_VBZ ._. Ideal_NN circumstances_NNS would_MD allow_VB
        for_IN the_DT development_NN of_IN cost_NN estimates_NNS based_VBN on_IN a_DT
        comprehensive_JJ study_NN ,_, designed_VBD not_RB to_TO influence_VB resource_NN
        use_NN ,_, of_IN unselected_JJ patients_NNS with_IN sufficient_JJ follow-up_JJ ._.
        Unfortunately_RB ,_, that_IN ideal_JJ rarely_RB exists_VBZ ._. This_DT cost_NN estimate_NN
        created_VBN by_IN assembling_VBG existing_VBG Canadian_JJ data_NNS provides_VBZ
        health_NN care_NN decision_NN makers_NNS in_IN Canada_NNP ,_, who_WP cannot_NN wait_NN for_IN
        the_DT ideal_JJ data_NN to_TO accumulate_VBP ,_, key_JJ information_NN heretofore_RB
        unavailable_JJ ._.
      
      
        Conclusion_NNP
        While_IN health_NN care_NN promotion_NN and_CC education_NN are_VBP valuable_JJ
        tools_NNS in_IN the_DT fight_NN against_IN diabetes_NN ,_, the_DT condition_NN and_CC its_PRP$
        complications_NNS will_MD continue_VB to_TO have_VB a_DT profound_JJ impact_NN on_IN
        the_DT health_NN of_IN Canadians_NNPS ,_, as_RB well_RB as_IN provincial_JJ and_CC national_JJ
        health_NN care_NN budgets_NNS for_IN the_DT foreseeable_JJ future_NN ._. New_JJ
        treatments_NNS are_VBP being_VBG developed_VBN to_TO improve_VB glycemic_JJ control_NN
        in_IN those_DT with_IN diabetes_NN with_IN the_DT goal_NN of_IN preventing_VBG or_CC
        delaying_VBG some_DT of_IN the_DT devastating_JJ complications_NNS associated_VBN
        with_IN the_DT disease_NN ._. While_IN appropriate_JJ medical_JJ care_NN of_IN the_DT
        patient_NN should_MD be_VB the_DT prevailing_VBG factor_NN for_IN all_DT health_NN care_NN
        decision_NN makers_NNS ,_, whether_IN at_IN the_DT care_NN delivery_NN or_CC the_DT policy_NN
        level_NN ,_, economic_JJ factors_NNS cannot_NN be_VB ignored_VBN ._. In_IN order_NN to_TO
        determine_VB which_WDT therapeutic_JJ agents_NNS are_VBP appropriate_JJ for_IN use_NN ,_,
        cost-effectiveness_JJ ,_, as_RB well_RB as_IN efficacy_NN and_CC safety_NN should_MD
        be_VB weighed_VBN ._. The_DT estimates_NNS in_IN this_DT analysis_NN do_VBP not_RB provide_VB
        cost-effectiveness_JJ information_NN for_IN any_DT type_NN of_IN treatment_NN
        for_IN diabetes_NN ,_, but_CC we_PRP believe_VBP that_IN they_PRP do_VBP provide_VB valuable_JJ
        cost_NN inputs_NNS for_IN any_DT researcher_NN or_CC policy_NN maker_NN who_WP needs_VBZ
        such_JJ information_NN to_TO carry_VB out_RP an_DT economic_JJ analysis_NN ._.
      
      
        Abbreviations_NNP
        AÉTMIS_NNP -_: Agence_NNP d_SYM '_POS évaluation_NN des_NNP technologies_NNS et_CC des_NNP
        modes_NNS d_SYM '_POS intervention_NN en_IN santé_NN
        AKA_NNP -_: above_IN the_DT knee_NN amputation_NN
        AMI_NNP -_: acute_JJ myocardial_NN infarction_NN
        CABG_NNP -_: coronary_JJ artery_NN bypass_NN graft_NN
        CMGs_NNP -_: case_NN mix_NN groupings_NNS
        ECG_NNP -_: electrocardiogram_NN
        ESRD_NNP -_: end-stage_JJ renal_JJ disease_NN
        ICD-_NNP 9_CD -_: International_NNP Classification_NNP of_IN Diseases_NNP
        LEAs_NNP -_: lower_JJR extremity_NN amputations_NNS
        LOS_NNP -_: length_NN of_IN stay_NN
        ME_NNP -_: macular_NN edema_NN
        MI_NNP -_: myocardia_NN infarction_NN
        OCCP_NNP -_: Ontario_NNP Case_NNP Cost_NN Project_NNP
        PTCA_NNP -_: percutaneous_JJ transluminal_NN coronary_JJ
        angioplasty_NN
        TIA_NNP -_: transient_JJ ischemic_JJ attacks_NNS
        US_NNP -_: United_NNP States_NNPS
        US_NNP $_$ -_: United_NNP States_NNPS dollars_NNS
      
    
  
